Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN

Oncology Letters

Volumn 5, Issue 6, 2013, Pages 1819-1825

  Okabayashi, Takehiro ^a   Shima, Yasuo ^a   Kosaki, Takuhiro ^b   Sumiyoshi, Tatsuaki ^a   Kozuki, Akihito ^a   Iiyama, Tastuo ^c   Takezaki, Yuka ^b   Kobayashi, Michiya ^b   Nishimori, Isao ^b   Ogawa, Yasuhiro ^b   Hanazaki, Kazuhiro ^b  

^a Kochi Health Sciences Center   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Intraductal papillary mucinous neoplasm; Management; Prognosis; SMAD4; Surgery; TGF

Indexed keywords

MESSENGER RNA; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS RESECTION; PATHOLOGICAL ANATOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 84876503220     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1268     Document Type: Article

References (30)

1. Tanaka M: Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol 8: 56-60, 2011.
2. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60: 1712-1720, 2011.
3. Fernández-del Castillo C and Adsay VN: Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 139: 708-713, 2010.
4. Loftus EV Jr, Olivares-Pakzad BA, Batts K P, et al: Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology 110: 19 09-1918, 1996.
5. Azar C, Van de Stadt J, Rickaert F, et al: Intraductal papillary and mucinous tumour of the pancreas. Clinical and therapeutic issues in 32 patients. Gut 39: 457-464, 1996.
6. Tanaka M, Chari S, Adsay V, et al: International Association of Pancreatology. International Consensus Guidelines for management of intraductal papillary mucinous neoplasms andmucinous cystic neoplasms of the pancreas. Pancreatology 6: 17-32, 2006.
7. Salvia R, Fernández-del Castillo C, Bassi C, et al: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 239: 678-685, 2004.
8. Okabayashi T, Kobayashi M, Nishimori I, et al: Clinico-pathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol 21: 462-467, 2006.
9. Uehara H, Ishikawa O, Ikezawa K, et al: A natural course of main duct intraductal papillary mucinous neoplasm of the pancreas with lower likelihood of malignancy. Pancreas 39: 653-657, 2010.
10. Arlix A, Bournet B, Otal P, et al: Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 41: 295-301, 2012.
11. Garcea G and Dennison AR: Branch-type intraductal papillary mucinous neoplasms: an update. Pancreatology 11: 336-342, 2011.
12. Okabayashi T, Nishimori I, Maeda H and Hanazaki K: Incidence of and predictive risk factors for intraductal papillary mucinous neoplasm of the pancreas with ordinary pancreatic cancer. J Clin Gastroenterol 44: 75-76, 2010.
13. Matthaei H, Norris AL, Tsiatis AC, et al: Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255: 326-333, 2012.
14. Maguchi H, Tanno S, Mizuno N, et al: Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas 40: 364-370, 2011.
15. Tanno S, Nakano Y, Nishikawa T, et al: Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut 57: 339-343, 2008.
16. Rautou PE, Lévy P, Vullierme M P, et al: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol 6: 807-814, 2008.
17. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
18. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117, 2010.
19. Kang MJ, Jang J Y, Kim SJ, et al: Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 9: 87-93, 2011.
20. Linton K, Hey Y, Dibben S, et al: Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques 47: 587-596, 2009.
21. Yang J, Ikezoe T, Nishioka C, et al: Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer 130: 959-966, 2012.
22. Rodriguez JR, Salvia R, Crippa S, et al: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 133: 72-79, 2007.
23. Salvia R, Crippa S, Falconi M, et al: Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 56: 1086-1090, 2007.
24. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 157: 755-761, 2000.
25. Pedrazzoli S, Sperti C, Pasquali C, Bissoli S and Chierichetti F: Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 254: 971-976, 2011.
26. Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006.
27. Zavadil J and Böttinger EP: TGFbeta and epithelial-to-mesen-chymal transitions. Oncogene 24: 5764-5774, 2005.
28. Bardeesy N, Cheng KH, Berger JH, et al: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146, 2006.
29. Braga M, Capretti G, Pecorelli N, et al: A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg 254: 702-707, 2011.
30. Poultsides GA, Reddy S, Cameron JL, et al: Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251: 470-476, 2010.